Literature DB >> 18187662

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Ramiro Garzon1, Stefano Volinia, Chang-Gong Liu, Cecilia Fernandez-Cymering, Tiziana Palumbo, Flavia Pichiorri, Muller Fabbri, Kevin Coombes, Hansjuerg Alder, Tatsuya Nakamura, Neal Flomenberg, Guido Marcucci, George A Calin, Steven M Kornblau, Hagop Kantarjian, Clara D Bloomfield, Michael Andreeff, Carlo M Croce.   

Abstract

MicroRNAs (miRNAs) are small RNAs of 19 to 25 nucleotides that are negative regulators of gene expression. To determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute myeloid leukemia (AML), we evaluated the miRNA expression of CD34(+) cells and 122 untreated adult AML cases using a microarray platform. After background subtraction and normalization using a set of housekeeping genes, data were analyzed using Significance Analysis of Microarrays. An independent set of 60 untreated AML patients was used to validate the outcome signatures using real-time polymerase chain reaction. We identified several miRNAs differentially expressed between CD34(+) normal cells and the AML samples. miRNA expression was also closely associated with selected cytogenetic and molecular abnormalities, such as t(11q23), isolated trisomy 8, and FLT3-ITD mutations. Furthermore, patients with high expression of miR-191 and miR-199a had significantly worse overall and event-free survival than AML patients with low expression (overall survival: miR-191, P = .03; and miR-199a, P = .001, Cox regression). In conclusion, miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations. A small subset of miRNAs is correlated with survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187662      PMCID: PMC2265455          DOI: 10.1182/blood-2007-07-098749

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Manuela Ferracin; Amelia Cimmino; Gianpiero Di Leva; Masayoshi Shimizu; Sylwia E Wojcik; Marilena V Iorio; Rosa Visone; Nurettin Ilfer Sever; Muller Fabbri; Rodolfo Iuliano; Tiziana Palumbo; Flavia Pichiorri; Claudia Roldo; Ramiro Garzon; Cinzia Sevignani; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

3.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  mir-29 regulates Mcl-1 protein expression and apoptosis.

Authors:  J L Mott; S Kobayashi; S F Bronk; G J Gores
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

6.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.

Authors:  Lee P Lim; Nelson C Lau; Philip Garrett-Engele; Andrew Grimson; Janell M Schelter; John Castle; David P Bartel; Peter S Linsley; Jason M Johnson
Journal:  Nature       Date:  2005-01-30       Impact factor: 49.962

7.  miR-15 and miR-16 induce apoptosis by targeting BCL2.

Authors:  Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-15       Impact factor: 11.205

8.  Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia.

Authors:  S M Kornblau; M Womble; J S Cade; E Lemker; Y H Qiu
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

9.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

Review 10.  The role of allogeneic transplantation in high-risk acute myelogenous leukemia.

Authors:  W R Drobyski
Journal:  Leukemia       Date:  2004-10       Impact factor: 11.528

View more
  268 in total

1.  Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.

Authors:  Seyed H Ghaffari; Davood Bashash; Majid Zaki Dizaji; Ardeshir Ghavamzadeh; Kamran Alimoghaddam
Journal:  Tumour Biol       Date:  2011-11-10

2.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

Authors:  Zejuan Li; Hao Huang; Yuanyuan Li; Xi Jiang; Ping Chen; Stephen Arnovitz; Michael D Radmacher; Kati Maharry; Abdel Elkahloun; Xinan Yang; Chunjiang He; Miao He; Zhiyu Zhang; Konstanze Dohner; Mary Beth Neilly; Colles Price; Yves A Lussier; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Lars Bullinger; Peter J M Valk; Ruud Delwel; Bob Lowenberg; Paul P Liu; Guido Marcucci; Clara D Bloomfield; Janet D Rowley; Jianjun Chen
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

3.  miR-10a contributes to retinoid acid-induced smooth muscle cell differentiation.

Authors:  Huarong Huang; Changqing Xie; Xuan Sun; Raquel P Ritchie; Jifeng Zhang; Y Eugene Chen
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

Review 4.  Pathogenesis of diffuse large B cell lymphoma.

Authors:  Wing John C Chan
Journal:  Int J Hematol       Date:  2010-06-29       Impact factor: 2.490

5.  Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience.

Authors:  Peter Schellongowski; Thomas Staudinger; Michael Kundi; Klaus Laczika; Gottfried J Locker; Andja Bojic; Oliver Robak; Valentin Fuhrmann; Ulrich Jäger; Peter Valent; Wolfgang R Sperr
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

6.  Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Sebastian Schwind; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Susan P Whitman; Christopher Hickey; Heiko Becker; Klaus H Metzeler; Peter Paschka; Claudia D Baldus; Shujun Liu; Ramiro Garzon; Bayard L Powell; Jonathan E Kolitz; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

Review 7.  Causes and consequences of microRNA dysregulation.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

8.  MicroRNA-125a inhibits cell growth by targeting glypican-4.

Authors:  Chao Feng; Jie Li; Jinlan Ruan; Kan Ding
Journal:  Glycoconj J       Date:  2012-05-27       Impact factor: 2.916

9.  Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer.

Authors:  Gholam Basati; Amirnader Emami Razavi; Iraj Pakzad; Fardin Ali Malayeri
Journal:  Tumour Biol       Date:  2015-08-29

10.  miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.

Authors:  Jared A Wallace; Dominique A Kagele; Anna M Eiring; Carissa N Kim; Ruozhen Hu; Marah C Runtsch; Margaret Alexander; Thomas B Huffaker; Soh-Hyun Lee; Ami B Patel; Timothy L Mosbruger; Warren P Voth; Dinesh S Rao; Rodney R Miles; June L Round; Michael W Deininger; Ryan M O'Connell
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.